Ligand Pharmaceuticals Incorporated (LGND) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with LGND
Recent news

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
LGND

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
LGND

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
LGND

Ligand Pharmaceuticals Q2 Earnings Call Highlights
Ligand Pharmaceuticals Q2 Earnings Call Highlights
LGND
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.76
- MACD 12/26/9
- 2.96
- EMA 9 of MACD
- 3.54
- MACD histogram
- -0.57
- SMA 50
- $292.04
- Price above SMA 50
- EMA 50
- $292.23
- Price above EMA 50
- SMA 200
- $244.30
- Price above SMA 200
- EMA 200
- $248.34
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
LGND

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
LGND

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
LGND

Ligand Pharmaceuticals Q2 Earnings Call Highlights
Ligand Pharmaceuticals Q2 Earnings Call Highlights
LGND

Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter
Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter
LGND

3 Overlooked Stocks Positioned for the Next Market Rotation
3 Overlooked Stocks Positioned for the Next Market Rotation
LGND

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
LGND

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
LGND

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
LGND

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
LGND
News tone: automated (AI) classification of the article's content, not a price prediction.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Todd C. Davis Ph.D. | CEO & Director | 1961 |
| Mr. Octavio Espinoza | Chief Financial Officer | 1971 |
| Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary | 1975 |
| Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development | — |
| Ms. Melanie J. Herman CPA | Executive Director of Investor Relations and Financial Planning & Analysis | 1979 |
| Ms. Marjorie Fackovec | Head of People Operations | — |
| Dr. Keith Marschke Ph.D. | Senior Vice President of Biology & Scientific Affairs | — |
| Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations & QA - Capitsol | 1969 |
| Dr. Karen R. Reeves M.D. | Senior VP of Investments & Head of Clinical Strategy | 1950 |
| Mr. Richard B. Baxter | Senior VP of Investment Operations | 1963 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 54.76
- MACD 12/26/9
- 2.96
- EMA 9 of MACD
- 3.54
- MACD histogram
- -0.57
- SMA 50
- $292.04
- Price above SMA 50
- EMA 50
- $292.23
- Price above EMA 50
- SMA 200
- $244.30
- Price above SMA 200
- EMA 200
- $248.34
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $326.00
- Average
- $350.17
- High
- $397.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +13.4 | +6.9 | +0.2 | |||||||||
| 2022 | -17.8 | -17.4 | +15.0 | -20.7 | -7.5 | +3.8 | +1.6 | +3.0 | -8.5 | +0.7 | -13.8 | -4.6 |
| 2023 | +5.6 | +2.1 | -0.5 | +6.7 | -8.7 | +1.3 | -7.9 | -1.4 | -9.9 | -11.6 | +9.4 | +21.6 |
| 2024 | +1.1 | +7.0 | -7.1 | -5.0 | +19.1 | -4.2 | +17.2 | |||||
| 2026 | +4.1 | -7.8 | -2.7 | +9.9 | -0.3 |



